에 대한 최신 뉴스 Meituan (OTC:MPNGY) 주식

Meituan is the largest food delivery platform in China, with a 60%-70% share of the market in 2024, according to Morningstar estimates. In the third quarter of 2024, the firm generated 74% of its revenue from the core local commerce segment, which includes on-demand food delivery and retail, in-store services (such as visiting beauty and entertainment stores after purchasing deals on Meituan), and hotel and travel booking. The remaining 26% of revenue came from the new initiatives segment, such as the community group purchase business Meituan Select and the overseas food delivery business.

Asia

Equities

News

Markets

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

BIDU

JDCMF

MPNGY

TCEHY

목요일(6일) 오전 홍콩 증시는 항셍지수가 2.5% 상승한 24,183.07포인트를 기록하며 2022년 1월 이후 최고치를 기록했다. 연간 상승률은 23.37%로 확대되었다.무슨 일 있었나: 홍콩증권거래소에서 중국 기술 대기업들이 랠리를 주도했다.

알리바바, 중국 정부의 AI 지원 약속에 주가 7% 상승...항셍지수 2년래 최고점

US CHINA Photo by Khanthachai C on Shutterstock

Tech

Media

MPNGF

NVDA

중국의 주요 기술 기업인 알리바바(NYSE:BABA), 바이트댄스, 메이투안(OTC:MPNGY)(OTC:MPNGF) 등이 실리콘밸리에서 인공지능(AI) 팀을 확장하고 있는 것으로 알려졌다.

알리바바, 바이트댄스, 메이투안 등 中 기술 대기업들, 실리콘밸리에서 AI 팀 확장 중인 이유는?

Meituan

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire five years after the date of issuance, and the Series E short-term warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire 18 months after the date of issuance. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions.
Total gross proceeds to the Company from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be $5.0 million. The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a cash basis, will be $10.0 million. No assurance can be given that any of such warrants will be exercised. The Company intends to use the net proceeds from this offering to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes. &nbsp;

Offerings

BBLG

BBLGW

Bone Biologics Prices $5M Public Offering At $4.00/Shr With Series D And E Warrants

<h2 class="wp-block-heading">New On The Block</h2>
Bahama Breeze may soon be <a href="https://www.benzinga.com/general/restaurants">gone with the wind</a>. 
Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is considering selling the Caribbean-inspired chain or repurposing all its locations.
The decision comes after Darden closed 15 Bahama Breeze restaurants in May, leaving just 28. Guru Focus <a href="https://www.gurufocus.com/news/2938406/darden-to-explore-strategic-alternatives-for-bahama-breeze-chain?r=caf6fe0e0db70d936033da5461e60141">reported</a> that CEO Rick Cardenas told analysts that future investments in the brand are off the table.
Initially launched in the 1990s, Bahama Breeze served up tropical vibes with dining options like coconut shrimp and empanadas. However, after a strategic review, Darden decided it was time to focus on other properties, such as the never-ending-pasta-bowl innovator Olive Garden.
<h2 class="wp-block-heading">Updates From The Block</h2>
Businessman Mark Walter has agreed to acquire a majority stake in the NBA's Los Angeles Lakers from the Buss Family Trust. Jeanie Buss will continue to oversee team operations. Walter, already a minority owner, also leads TWG Global, which holds stakes in several sports properties.
The Buss family has owned the Lakers since 1979, overseeing 11 NBA championships and shaping one of the most recognized franchises in global sports. The team has featured iconic players such as Magic Johnson, Kareem Abdul-Jabbar, Kobe Bryant, Shaquille O'Neal and LeBron James.
The deal is expected to close in late 2025, pending NBA approval and other standard conditions.
Guggenheim Securities is advising Walter, with legal support from Davis Polk &amp; Wardwell LLP. ArentFox Schiff LLP represents the Lakers and the Buss Family Trust.
More Updates:
<ul class="wp-block-list">
<li>Recall in 2021 how Best Buy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) acquired remote care management platform Current Health. It&#8217;s now selling it <a href="https://www.linkedin.com/feed/update/urn:li:activity:7343300338491305984/">back</a> to co-founder Christopher McGhee for $400 million.</li>
<li>Maserati isn&#8217;t for sale. That&#8217;s according to Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), the owner, which <a href="https://www.reuters.com/business/autos-transportation/jeep-maker-stellantis-weighs-sale-among-options-maserati-sources-say-2025-06-20/?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axioscloser&amp;stream=top">responded</a> to a Reuters report.</li>
<li>U.S. antitrust regulators approved Mars&#8216; proposed $35.9 billion purchase of snackmaker Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>). In Europe, however, antitrust <a href="https://www.benzinga.com/m-a/25/06/46113916/mars-just-got-the-green-light-for-its-36b-deal-but-europe-might-blow-it-up">regulators are investigating the deal</a>.</li>
<li>New Zealand-based accounting software firm Xero will acquire U.S. bill-pay platform Melio for an initial $2.5 billion, according <a href="https://www.wsj.com/business/deals/xero-to-buy-melio-for-initial-2-5-billion-in-u-s-growth-play-eb0d46af?mod=deals_news_article_pos2">to</a> the Wall Street Journal. Melio shareholders, including Accel and Thrive Capital, will receive $360 million in Xero shares. Xero, which reported approximately $1.26 billion in revenue for its last fiscal year, stated that revenue could double over the next three years, excluding anticipated synergies. Melio CEO Matan Bar will lead Xero's U.S. business post-acquisition.</li>
<li>Bank of New York Mellon placed an offer for Chicago-based Northern Trust, which has a market value of more than $21 billion. The Trump administration has <a href="https://www.reuters.com/markets/deals/big-bank-deals-stalled-by-trump-volatility-even-officials-signal-deregulation-2025-03-14/">signaled</a> a greater willingness to approve large banking deals, but few have been completed.</li>
<li>Woody Johnson is the latest rich American to buy a different football club. The billionaire agreed to pay just $215 million for a &#8220;significant&#8221; stake in Premier League club Crystal Palace, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-06-23/ny-jets-owner-woody-johnson-agrees-deal-for-crystal-palace-stake?sref=TBDibEcD">reports</a>. On the sell side is John Textor. Let&#8217;s hope Crystal Palace has better luck than the New York Jets, which has been under the miserable ownership of Johnson since January 2000.</li>
<li>Unilever signed an agreement to acquire personal care brand Dr. Squatch from growth equity firm Summit Partners. The price tag was not disclosed, but Women&#8217;s Wear Daily <a href="https://wwd.com/beauty-industry-news/skin-care/unilever-personal-care-acquisition-dr-squatch-1237941602/">reported</a> that the company&#8217;s sales exceeded $400 million.</li>
</ul>
<h2 class="wp-block-heading">Off The Block</h2>
<ul class="wp-block-list">
<li>The NBA&#8217;s board of governors approved the $1.5 billion sale of the Minnesota Timberwolves and WNBA's Minnesota Lynx from longtime owner Glen Taylor to an investment group led by entrepreneur Marc Lore and former MLB star Alex Rodriguez. The unanimous vote concludes a four-year back-and-forth process that included arbitration after Taylor attempted to cancel the deal earlier this year. Taylor, who bought the Timberwolves in 1994 to prevent a relocation to New Orleans, leaves after 31 years with the team. Lore and Rodriguez pledged to keep the teams in Minnesota.</li>
</ul>
<ul class="wp-block-list">
<li>Parkland (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PKI#TSX">PKI</a>), a Canadian fuel distributor, confirmed that shareholders voted in favor of a $9.1 billion takeover by Sunoco (YSE: SUN). The deal will form America&#8217;s largest independent fuel distributor.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul class="wp-block-list">
<li>You can still place bids on assets owned by Monster and CareerBuilder. The two online job search websites, which merged last year, <a href="https://www.wsj.com/articles/careerbuilder-monster-to-sell-businesses-in-bankruptcy-9daa38dd">filed</a> for Chapter 11 bankruptcy. So far, JobGet is looking to buy at least one asset. Canada-based Valsoft Corporation and Canadian media firm Valnet are keen on acquiring others, including Military.com, which Monster bought in 2004 for $39.5 million. Tough competition is to blame for the restructuring, says CEO Jeff Furman, citing Indeed, LinkedIn, and Glassdoor. Private equity firm Apollo Global Management holds a minority stake in the company.</li>
</ul>
<a href="https://www.benzinga.com/m-a/25/06/46038749/deal-dispatch-boston-red-sox-owner-sets-sights-on-la-liga-club-at-home-files-for-bankruptcy">For last week&#8217;s edition of Deal Dispatch, click here</a>. 
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46125266/thank-you-elon-musks-longtime-aide-reportedly-fired-days-after-public-praise">&#8216;Thank You, Elon:&#8217; Musk&#8217;s Longtime Aide Reportedly Fired Days After Public Praise</a></li>
</ul>
Image: Edited by Benzinga using Shutterstock

Asset Sales

Sports

STLA

TSX:PKI

Deal Dispatch: Darden Cools On Bahama Breeze, NBA M&A Heats Up

Wells Fargo analyst Finian O'Shea maintains Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) with a Overweight and raises the price target from $21 to $22.

Price Target

Analyst Ratings

ARCC

Wells Fargo Maintains Overweight on Ares Capital, Raises Price Target to $22

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.27</td>
<td align="right">0.30</td>
<td align="right">0.73</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.37</td>
<td align="right">1.36</td>
<td align="right">0.63</td>
<td>4.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">106.96</td>
<td align="right">0.53</td>
<td align="right">0.49</td>
<td>105</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">146.00</td>
<td align="right">0.66</td>
<td align="right">0.45</td>
<td>673</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.45</td>
<td align="right">0.28</td>
<td align="right">0.34</td>
<td>3.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">86.03</td>
<td align="right">0.28</td>
<td align="right">0.32</td>
<td>35.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">251.60</td>
<td align="right">0.53</td>
<td align="right">0.21</td>
<td>14.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.96</td>
<td align="right">0.18</td>
<td align="right">0.20</td>
<td>880</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.47</td>
<td align="right">0.25</td>
<td align="right">0.18</td>
<td>3.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.85</td>
<td align="right">0.06</td>
<td align="right">0.11</td>
<td>292.6K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.15</td>
<td align="right">-0.02</td>
<td align="right">-0.03</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 27, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.
Shares of Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) fell sharply in today's pre-market trading after the company posted mixed <a href="https://www.benzinga.com/quote/CNXC/earnings">second-quarter results</a>.
Concentrix reported quarterly earnings of $2.70 per share, which missed the analyst consensus estimate of $2.75. Quarterly revenue came in at $2.42 billion, which beat the Street estimate of $2.38 billion
Concentrix shares dipped 8% to $50.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) declined 14.2% to $12.83 in pre-market trading after the company announced an $85 million public offering.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) fell 14.2% to $3.14 in pre-market trading after surging more than 32% on Thursday.</li>
<li>AdaptHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) fell 8.6% to $8.61 in pre-market trading after gaining around 5% on Thursday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) declined 8.4% to $11.65 in pre-market trading.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) fell 5.1% to $22.60 in pre-market trading.</li>
<li>OMS Energy Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMSE#NASDAQ">OMSE</a>) fell 4.6% to $6.80 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutetrstock

Trading Ideas

AHCO

CNXC

CRMD

CRML

OMSE

USAR

Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session

RBC Capital analyst Drew McReynolds reiterates Corus Entertainment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CJR#TSX">CJR</a>) with a Sector Perform and maintains C$0.2 price target.

Reiteration

TSX:CJR

TSX:CJR/B

RBC Capital Reiterates Sector Perform on Corus Entertainment, Maintains C$0.2 Price Target

Select Medical Corporation today announced it signed a membership interest purchase agreement with Ballad Health to jointly operate Select Specialty Hospital – Tri-Cities, a critical illness recovery hospital in Kingsport, Tenn. The facility, licensed as long-term acute care, will be a hospital-in-hospital located in Ballad Health's Indian Path Community Hospital.&nbsp;
Select Medical will serve as the majority owner and managing partner of the 46-bed joint venture hospital with Ballad Health. The hospital, which is currently owned and operated by Select Medical, will relocate from Ballad Health's Bristol Regional Medical Center to Indian Path Community Hospital following regulatory approval.

Select Medical Signs Membership Interest Purchase Agreement With Ballad Health To Jointly Operate Select Specialty Hospital – Tri-Cities

RSLS

ReShape Lifesciences Regains Nasdaq Compliance Under Minimum Stockholders Equity Requirement

On June 25, 2025, Ralliant Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RALW#NYSE">RALW</a>), a spin-off of Fortive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTVW#NYSE">FTVW</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) <a href="https://gsbresearch.com/product/spinoff-analysis-fortive-and-ralliant-begin-when-issued-trading/">commenced when-issued trading</a> on the NYSE. 
Earlier on September 4, 2024, FTV announced plans to separate its Precision Technologies business into a separate publicly listed company, Ralliant Corp, via a tax-free spin-off transaction. The parent will retain the Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) business segments, boasting a portfolio with 50% recurring revenue. We see the spin-off as a move to streamline operations and accelerate business growth, thereby unlocking value for shareholders. The spin-off will allow Fortive to focus on high-growth, high-margin businesses in software and connected devices. The Precision Technologies business is more capital-intensive and has stable but slower growth than the parent. The separation will allow Ralliant to allocate capital and resources more efficiently towards its needs, such as R&amp;D for advanced instrumentation or acquisitions within its niche.
The record date for the distribution of Ralliant shares was June 16, 2025. Each FTV shareholder will receive 1 share of Ralliant for every 3 shares of FTV held as of the record date. The regular-way trading will begin on June 30, 2025. Ralliant will trade under the ticker ‘RAL' and Fortive (ex Ralliant) will continue to trade under the ticker ‘FTV'. The spin-off of Ralliant will be effective on June 28. The transaction is intended to qualify as tax-free to Fortive shareholders.
Following the completion, Olumide Soroye, the current leader of Fortive's intelligent operations division, will assume the position of CEO. Meanwhile, Tami Newcombe, the current overseer of the Precision Technologies and Advanced Health-Care units, will take charge of Ralliant Corp.
As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. RAL will assume debt to pay the cash dividend to FTV and commence its journey as a standalone company with a leverage of 1.9x.
INVESTMENT HIGHLIGHTS
Fortive (ex Ralliant)
Post the separation, Fortive will comprise the portfolio brands such as Accruent, Fluke, Gordian, Censis, Provation, currently operating under Fortive's two business segments – Intelligent Operating Solutions (iOS) and Advanced Healthcare Solutions (AHS). The two business segments generate nearly 50% recurring revenue and have demonstrated lower volatility across cycles.
FTV (ex Ralliant) will be $4 billion in revenues, with 65% adjusted gross margins and 29% adjusted EBITDA margins. The business generated about $1 billion in free cash flow over the last twelve months with an adjusted net income to FCF conversion of more than 100%. Over the last five years, it has delivered 4% core revenue CAGR.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="906" height="117" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png" alt="" class="wp-image-14985" style="width:850px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png 906w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-300x39.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-768x99.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></figure>
Intelligent Operating Solutions (IOS). IOS is Fortive's largest segment, accounting for nearly 70% of the revenue post spin-off. It houses flagship brands such as Fluke (electrical and industrial test tools), Industrial Scientific (gas detection and worker safety), Accruent and Gordian (enterprise asset management), and ServiceChannel (facility maintenance SaaS platform). The segment serves diverse end markets predominantly industrial, government, retail &amp; consumer. Geographically, U.S. accounts for the largest revenue contribution at 56% of total, followed by Europe at 17% and China at 8%.
Advanced Healthcare Solutions (AHS). The AHS segment supplies critical workflow solutions critical for patient care. This includes instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. The AHS segment has a recurring revenue base at nearly 80% with adjusted EBITDA margins in high 20s. The addressable market across AHS verticals exceeds $10 billion, with low single-digit to mid-single digit growth potential.
Capital Structure. As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. Of which, $700 million will be used to repay debt. The remaining will be used for share buyback under its $550 million share repurchase authorization program. Pro forma debt post spin-off is expected to be $3.2 billion, with cash &amp; cash equivalents at $1.2 billion. Based on TTM Q1 2025 adjusted EBITDA, leverage is 2.7x, with the target to bring it down to 2.5x in the next 12-18 months.
Ralliant Corp
Ralliant Corp will include the Precision Technologies business comprising a portfolio of brands such as Gems, Tektronix, Setra, Qualitrol, among others. It offers advanced instrumentation and precision measurement solutions to aerospace, defense, electronics, automotive, and industrial manufacturing.
The Company will operate via two segments &#8211; Test and Measurement (~56% of total sales) and Sensors and Safety Systems (44% of total sales).
Capital Structure
As part of the transaction, Ralliant will issue new debt of $1.15 billion via a term loan. The proceeds will be used to fund the cash distribution to Fortive. Pro forma cash post the transaction will be $150 million, implying a net debt of $1.0 billion. Additionally, RAL will have access to a total liquidity of $900 million comprising an undrawn revolving credit facility of $750 million and $150 million in undrawn term loans. Based on TTM Q1 2025 adjusted EBITDA, leverage is 1.9x, which is within the Company's target range of 1.5x-2.0x.
Financial Outlook
FTV (ex RAL)
We expect FTV (ex RAL) to deliver revenue growth of 3.6% in FY25. We expect margins to expand, supported by higher mix of recurring revenue and operating leverage. As such, we model EBITDA margins of 29% in FY25, up 50 bps YOY. The combination of solid revenue growth and margin expansion should drive EPS higher. We model adjusted EPS of $2.56 in FY25, up 6% YOY.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="710" height="148" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png" alt="" class="wp-image-14987" style="width:506px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png 710w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9-300x63.png 300w" sizes="(max-width: 710px) 100vw, 710px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Ralliant Corp (RAL)
We expect RAL to deliver revenue growth of 3.5% in FY25 and 4.0% in FY:26. We expect adjusted EBITDA to grow faster than revenue, implying margin expansion. As such, we model EBITDA margins of 23.7% in FY25 and 23.9% in FY:26. We forecast adjusted EPS of $3.40 in FY25 and $3.60 in FY26.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="704" height="170" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png" alt="" class="wp-image-14988" style="width:501px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png 704w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10-300x72.png 300w" sizes="(max-width: 704px) 100vw, 704px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Valuation
FTV (ex RAL) 
We value FTV (ex RAL) using the EV/EBITDA multiple. We value IOS segment at 19x 2026E adjusted EBITDA of $1,049 million, and ASH segment at 12.6x 2026E adj. EBITDA of $395 million, in line with the peer group average. Corporate expense is valued at 12x. We use debt of ~$3.2 billion and cash of $1.2 billion (factoring in ~$1.15 billion of proceeds from RAL which will be used to pare debt). We assume ~339 million shares outstanding. Our 12-month price target is $62.70.
Ralliant Corp (RAL) 
We value RAL using the EV/EBITDA multiple. We apply a multiple of 12.4x 2026E adjusted EBITDA of $557 million, at a discount to the peer group average given RAL's lower growth and margin profile and higher debt. We assume ~113 million shares outstanding. Our 12-month price target is $52.40.

Conclusion: Of the two, Fortive (ex RAL) seems a better investment opportunity and could attract higher investor interest given its higher margin profile, reducing debt and share buyback program.

Long Ideas

Opinion

Fortive Corporation Common Stock When-Issued

FTVW

RALW

Fortive Or Its Spin-Off Ralliant: Which Stock Is A Better Buy?

WETH

WeTouch Secures Nasdaq Extension To File Delinquent 10-K And 10-Q Reports

RBC Capital analyst Irene Nattel reiterates Alimentation Couche-Tard (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATD#TSX">ATD</a>) with a Outperform and maintains C$94 price target.

TSX:ATD

RBC Capital Reiterates Outperform on Alimentation Couche-Tard, Maintains C$94 Price Target

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced that it has entered into definitive agreements in a registered direct offering with a single institutional investor for the purchase and sale of approximately $17.2 million of shares of Common Stock and pre-funded warrants at a price of $7.50 per share of Common Stock. Upon closing of the offering, the Company will have fully utilized its shelf registration statement.

Cyngn Announces $17.2M Registered Direct Offering At $7.50/Shr

WIIM

Alpha Pro Tech shares are trading higher after the company's board authorized a $2 million expansion of its share repurchase program.

Buybacks

Alpha Pro Tech Board Authorizes $2M Expansion Of Share Repurchase Program

In a potential game-changer for the cryptocurrency mining sector, Morgan Stanley has forecasted that CoreWeave Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) proposed acquisition of Core Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) could boost the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner&#8217;s market capitalization by an impressive $2.8 billion.
What Happened: This Morgan Stanley analysis was shared by Eric Jackson from EMJ Capital amid renewed takeover discussions between the two companies, as reported by the Wall Street Journal, with a deal possibly finalizing within weeks if negotiations proceed smoothly.
&#8220;While the potential terms of a deal were not released, the estimated profits from the current contracts exceed Core Scientific's market cap by ~$2.8B,&#8221; said Jackson in his X post, quoting Morgan Stanley.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Morgan Stanley on the potential <a href="https://twitter.com/search?q=%24CRWV&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CRWV</a> &#8211; <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a> deal: While the potential terms of a deal were not released, the estimated profits from the current contracts exceed Core Scientific's market cap by ~$2.8B (with CORZ market cap at ~$4.95B today).
&mdash; Eric Jackson (@ericjackson) <a href="https://twitter.com/ericjackson/status/1938421603253235836?ref_src=twsrc%5Etfw">June 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Core Scientific, currently valued at approximately $4.87 billion, rejected $5.75 per share offer from CoreWeave a year ago. The company operates one of North America's largest digital infrastructure platforms focused on bitcoin mining and hosting.
The company's strategic 12-year hosting partnership with CoreWeave, which provides 590 MW of capacity across 12 contracts valued at $10 billion, underpins this growth.
&#8220;Core Scientific receives a 75%-80% profit margin on the CoreWeave contract, which implies that Core Scientific receives a profit of ~$7.75bn at the midpoint,&#8221; Jackson highlighted in another post.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46108861/microsoft-is-playing-chess-and-others-are-playing-checkers-dan-ives-says-msft-could-be-a-5-trillion-company-in-18-months">Microsoft Is &#8216;Playing Chess, And Others Are Playing Checkers:&#8217; Dan Ives Says MSFT Could Be A $5 Trillion Company In 18 Months</a>
Why It Matters: CoreWeave, a $75.87 billion cloud infrastructure giant serving AI workloads for clients like Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), is funding up to $750 million in data center build-outs, with Core Scientific contributing just $104 million.
&#8220;Core Scientific receives a 75%-80% profit margin on the CoreWeave contract, which implies that Core Scientific receives a profit of ~$7.75bn at the midpoint,&#8221; explained Jackson.
Price Action: CRWV shares were up 1.97% in premarket on Friday and ended 0.89% lower on Thursday. It has risen by 295.20% since its listing in March.
Benzinga Edge Stock Rankings shows that CRWV had a stronger price trend over the short, medium, and long term. Its value ranking was poor at the 9.72nd percentile. The details are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="156" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-1024x156.png" alt="" class="wp-image-964838" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-1024x156.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-768x117.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
CORZ shares were up 7.89% in premarket on Friday and ended 33.01% higher on Thursday. It has risen by 12.98% on a year-to-date.
Benzinga Edge Stock Rankings shows that CORZ had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid; however, its value ranking was poor at the 16.3rd percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="162" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-1024x162.png" alt="" class="wp-image-964835" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-1024x162.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-300x47.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-768x121.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE.png 1033w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Thursday. The SPY was up 0.39% at $614.24, while the QQQ advanced 0.46% to $548.73, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46112471/ross-gerber-touts-an-idea-to-cut-deficit-by-trillions-of-dollars-let-the-tax-cuts-e">Ross Gerber Touts An Idea To Cut Deficit By Trillions Of Dollars: &#8216;Let The Tax Cuts Expire And Full SALT Come Back&#8217; </a></li>
</ul>
Image Credit: Shutterstock

$BTC

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

MSFT

CRWV–CORZ Potential Deal Could Unlock $2.8 Billion Hidden Value For Bitcoin Miner, Says Morgan Stanley

TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.36, a high estimate of $16.00, and a low estimate of $10.90. Observing a downward trend, the current average is 18.79% lower than the prior average price target of $15.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029278_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive TAL Education is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alice Cai</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.54</td>
<td>$13.40</td>
</tr>
<tr>
<td>Linda Huang</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.90</td>
<td>$14.50</td>
</tr>
<tr>
<td>DS Kim</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>DS Kim</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TAL Education. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TAL Education compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of TAL Education's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into TAL Education's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on TAL Education analyst ratings.</a>
<h2>Discovering TAL Education: A Closer Look</h2>
TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
<h3>Unraveling the Financial Story of TAL Education</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: TAL Education's remarkable performance in 3M is evident. As of 28 February, 2025, the company achieved an impressive revenue growth rate of 42.06%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: TAL Education's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): TAL Education's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.19%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): TAL Education's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, TAL Education adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess TAL Education: What You Need To Know

Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.2, a high estimate of $17.00, and a low estimate of $6.00. Highlighting a 5.38% decrease, the current average has fallen from the previous average price target of $10.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029265_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Sprinklr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Matthew Vanvliet</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sprinklr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sprinklr compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sprinklr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CXM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sprinklr analyst ratings.</a>
<h2>Discovering Sprinklr: A Closer Look</h2>
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
<h3>Breaking Down Sprinklr's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Sprinklr showcased positive performance, achieving a revenue growth rate of 4.87% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Sprinklr's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sprinklr's ROE stands out, surpassing industry averages. With an impressive ROE of -0.25%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sprinklr's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.13% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sprinklr Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Biotech

General

CMND

Clearmind Medicine Adds Hadassah-University Medical Center As New Clinical Site For Phase I/IIa Trial Evaluating CMND-100

In the latest quarter, 8 analysts provided ratings for BeOne Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $324.38, with a high estimate of $350.00 and a low estimate of $311.00. This current average has decreased by 0.23% from the previous average price target of $325.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029256_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of BeOne Medicines by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$348.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$312.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$334.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$348.00</td>
<td>$348.00</td>
</tr>
<tr>
<td>Greg Renza</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$312.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BeOne Medicines. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BeOne Medicines compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BeOne Medicines's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ONC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BeOne Medicines analyst ratings.</a>
<h2>Get to Know BeOne Medicines Better</h2>
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
<h3>BeOne Medicines's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: BeOne Medicines's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 48.64%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): BeOne Medicines's ROE excels beyond industry benchmarks, reaching 0.04%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): BeOne Medicines's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.02% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: BeOne Medicines's debt-to-equity ratio is below the industry average. With a ratio of 0.28, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About BeOne Medicines

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has been analyzed by 26 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Uber Technologies and provided 12-month price targets. The average target is $95.65, accompanied by a high estimate of $110.00 and a low estimate of $80.00. This current average has increased by 7.04% from the previous average price target of $89.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029240_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Uber Technologies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$84.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Uber Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Uber Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Uber Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UBER/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Uber Technologies analyst ratings.</a>
<h2>About Uber Technologies</h2>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 170 million users who order rides or food at least once a month.
<h3>Key Indicators: Uber Technologies's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Uber Technologies's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.84% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Uber Technologies's net margin is impressive, surpassing industry averages. With a net margin of 15.4%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Uber Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Uber Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Uber Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBER

Forecasting The Future: 26 Analyst Projections For Uber Technologies

목요일(6일) 오전 홍콩 증시는 항셍지수가 2.5% 상승한 24,183.07포인트를 기록하며 2022년 1월 이후 최고치를 기록했다. 연간 상승률은 23.37%로 확대되었다.
무슨 일 있었나: 홍콩증권거래소에서 중국 기술 대기업들이 랠리를 주도했다. 알리바바 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#OTC">BABAF</a>) 주가가 7.24% 상승한 139.30 HKD($17.93), 텐센트(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) 주가가 5.84% 상승한 534.00 HKD($68.72)에 거래되었다.
다른 주요 기술 기업들도 상당한 상승세를 보였는데 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)는 3.83% 상승하여 90.80 HKD($11.68), JD닷컴(OTC:<a class="ticker" href="https://www.benzinga.com/stock/JDCMF#OTC">JDCMF</a>)은 4.06% 상승하여 171.20 HKD($22.03), 메이투안(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGY#OTC">MPNGY</a>)은 4.08% 상승하여 179.50 HKD($23.10)에 거래되었다.
로이터 통신은 수요일 중국 전국인민대표대회에서 리창 총리가 재정 부양책을 확대하겠다고 발표한 이후 시장 랠리가 이어졌다고 보도했다. 리 총리는 부진한 소비를 "적극적으로 부양"하고 미국 무역 긴장 고조로 인한 충격을 완화하는 동시에 2025년 중국의 5% 성장 목표를 유지하겠다고 약속했다.
리 총리는 "점점 더 복잡하고 어려워지는 외부 환경이 무역, 과학, 기술 등의 분야에서 중국에 더 큰 영향을 미칠 수 있다"고 경고하며 "한 세기 동안 보지 못한 변화"를 언급했다.
왜 중요한가: 중국은 올해 1.3조 위안(1,790 억 달러)의 초장기 특별 국채를 발행할 계획이며 2024년 1조 위안보다 증가한 수치다. 또한 지방 정부가 4.4조 위안의 특별 부채를 발행할 수 있도록 허용할 것이며, 예산 적자는 GDP의 약 4%까지 확대될 것으로 예상된다.
투자자들은 특히 리 총리가 전기차, 스마트폰, 로봇 전반에 걸쳐 인공지능(AI) 애플리케이션을 육성하겠다고 약속하면서 중국의 AI 야망에 열광하고 있는 것으로 보인다. 최근 AI 플랫폼 딥시크의 등장으로 시장 분위기는 더욱 고조되었으며, 알리바바도 오늘 새로운 QwQ-32B 추론 모델을 발표했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Today, we release QwQ-32B, our new reasoning model with only 32 billion parameters that rivals cutting-edge reasoning model, e.g., DeepSeek-R1.
Blog: <a href="https://t.co/zCgACNdodj">https://t.co/zCgACNdodj</a> HF: <a href="https://t.co/pfjZygOiyQ">https://t.co/pfjZygOiyQ</a> ModelScope: <a href="https://t.co/hcfOD8wSLa">https://t.co/hcfOD8wSLa</a> Demo: <a href="https://t.co/DxWPzAg6g8">https://t.co/DxWPzAg6g8</a> Qwen Chat:… <a href="https://t.co/kfvbNgNucW">pic.twitter.com/kfvbNgNucW</a>
&mdash; Qwen (@Alibaba_Qwen) <a href="https://twitter.com/Alibaba_Qwen/status/1897361654763151544?ref_src=twsrc%5Etfw">March 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

중국의 주요 기술 기업인 알리바바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), 바이트댄스, 메이투안(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGY#OTC">MPNGY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGF#OTC">MPNGF</a>) 등이 실리콘밸리에서 인공지능(AI) 팀을 확장하고 있는 것으로 알려졌다.
무슨 일 일어났나: <a href="https://www.ft.com/content/da8c29b0-0a90-4d2a-8535-c8459ccc7bb4">파이낸셜타임스 보도에 따르면</a> 중국 기술 대기업들은 최근 수익성 높은 AI 부문에서 우위를 점할 수 있도록 미국 최고의 인재를 유치하기 위해 캘리포니아에 기반을 둔 사무소를 확장하고 있다.
알리바바는 국제 상거래에 대한 광범위한 추진의 일환으로 검색엔진 AI인 아씨오(Accio)를 위한 엔지니어, 제품 관리자 및 AI 연구원을 채용하고 있다. 메이퇀은 AI 기반 메뉴 번역과 같은 기능에 중점을 둔 팀을 구성하고 있으며, 바이트댄스는 두바오(Doubao) 언어 모델을 지속적으로 개발하고 AI를 틱톡에 통합하고 있다.
이러한 확장은 미국이 AI 모델 개발에 필수적인 엔비디아의 하이엔드 AI 칩을 중국 기업에 <a href="https://www.benzinga.com/news/24/10/41323155/nvidia-amd-face-chip-export-curbs-as-biden-administration-considers-restrictions-on-middle-east-coun">수출하는 것을 금지한 상황</a>에서도 이루어졌다. 중국 기술 기업과 관련이 있거나 소유한 미국 기반 법인이 미국 데이터 센터를 통해 하이엔드 AI 칩에 액세스하는 데는 제한이 없다.
그러나 해당 보도는 미국 상무부가 지난 1월 클라우드 제공업체가 AI 모델을 훈련하는 사용자의 신원을 확인하고 활동을 보고하도록 요구하는 규칙을 제안했다고도 지적했다.
<a href="https://bztechtrends.beehiiv.com/subscribe">벤징가 테크 트렌드 뉴스레터</a>를 구독하고 최신 기술 개발 소식을 받아보세요.
왜 중요한가: 실리콘밸리에서 이러한 중국 거대 기술 기업의 확장은 미중 긴장이 고조되는 가운데 이루어지고 있다. 도널드 트럼프의 재선 성공 이후 양국 간의 <a href=""https://www.benzinga.com/government/24/11/41773691/us-listed-chinese-stocks-like-alibaba-jd-nio-fall-after-trumps-win-whats-going-on"">포괄적인 무역 갈등</a>이 발생할 수 있다는 우려가 있었다.
트럼프가 제안한 중국산 제품에 대한 60% 관세는 <a href="https://www.benzinga.com/markets/24/11/42028954/peter-thiel-says-trumps-60-china-tariff-would-be-very-very-bad-for-beijing-heres-whats-at-stake">중국 기업에 큰 영향을 미칠 것</a>으로 예상된다. 이에 트럼프의 승리 이후 알리바바, 징동닷컴, 니오 등 미국에 상장된 중국 주식은 하락세를 보였다.
그러나 시진핑 중국 국가주석은 집권하는 행정부와 상관없이 미국 정부와 <a href="https://www.benzinga.com/24/11/42025284/xi-jinping-tells-joe-biden-china-is-ready-to-work-with-trump-as-tariff-threat-looms">협력하겠다는 의지를 표명</a>했다.
그는 리마에서 열린 아시아태평양 경제협력체 포럼에서 조 바이든 미국 대통령에게 "중국은 양국 국민의 이익을 위해 대화를 유지하고, 협력을 확대하고, 입장 차이를 관리하기 위해 미국 정부와 협력할 준비가 되어 있다&#8221;고 말했다.
이미지 제공: 위키미디어 커먼즈 
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Meituan

뉴스

에 대한 최신 뉴스 Meituan (OTC:MPNGY) 주식

목요일, 3월 06, 2025

화요일, 11월 19, 2024

뉴스

파트너 / 기고자

벤징가 글로벌